Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Kedar

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Experimental Cell Research|November 8, 2001
Activation of HTLV-I long terminal repeat by stress-inducing agents and protection of HTLV-I-infected T-cells from apoptosis by the viral tax proteinA Torgeman, Z Ben-Aroya, A Grunspan, et al.
Cancer Research|May 15, 1990
Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamineW J Urba, L C Hartmann, D L Longo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 22, 2020
Imaging-based prostate cancer screening among BRCA mutation carriers-results from the first round of screeningN Segal, Y Ber, O Benjaminov, et al.
Breast Cancer Research and Treatment|May 27, 2016
Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutationsR Lewin, A Sulkes, T Shochat, et al.
Breast Cancer Research and Treatment|March 12, 2022
Common founder BRCA2 pathogenic variants and breast cancer characteristics in Ethiopian JewsS Lieberman, R Chen-Shtoyerman, Z Levi, et al.
Familial Cancer|April 10, 2021
A novel founder MSH2 deletion in Ethiopian Jews is mainly associated with early-onset colorectal cancerI Kedar, L Walsh, G Reznick Levi, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Experimental Cell Research|November 8, 2001
Activation of HTLV-I long terminal repeat by stress-inducing agents and protection of HTLV-I-infected T-cells from apoptosis by the viral tax proteinA Torgeman, Z Ben-Aroya, A Grunspan, et al.
Cancer Research|May 15, 1990
Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamineW J Urba, L C Hartmann, D L Longo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 22, 2020
Imaging-based prostate cancer screening among BRCA mutation carriers-results from the first round of screeningN Segal, Y Ber, O Benjaminov, et al.
Breast Cancer Research and Treatment|May 27, 2016
Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutationsR Lewin, A Sulkes, T Shochat, et al.
Breast Cancer Research and Treatment|March 12, 2022
Common founder BRCA2 pathogenic variants and breast cancer characteristics in Ethiopian JewsS Lieberman, R Chen-Shtoyerman, Z Levi, et al.
Familial Cancer|April 10, 2021
A novel founder MSH2 deletion in Ethiopian Jews is mainly associated with early-onset colorectal cancerI Kedar, L Walsh, G Reznick Levi, et al.
Pageof 5